69 related articles for article (PubMed ID: 30155683)
1. Effects of oral administration of nonselective Trk inhibitor on bladder overactivity in rodent models of prostatic inflammation.
Igarashi T; Mizoguchi S; Matsuoka K; Kamijo T; Kawano S; Furuta A; Suzuki Y; Kimura T; Pascal LE; Wang Z; Yoshimura N
Prostate; 2024 Aug; 84(11):1016-1024. PubMed ID: 38804836
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder.
Kashyap M; Kawamorita N; Tyagi V; Sugino Y; Chancellor M; Yoshimura N; Tyagi P
J Urol; 2013 Aug; 190(2):757-64. PubMed ID: 23454160
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats.
Wróbel A; Serefko A; Rechberger E; Banczerowska-Górska M; Poleszak E; Dudka J; Skorupska K; Miotła P; Semczuk A; Kulik-Rechberger B; Mandziuk S; Rechberger T
Eur J Pharmacol; 2018 Oct; 837():127-136. PubMed ID: 30172788
[TBL] [Abstract][Full Text] [Related]
4. Chronic Administration of 13-cis-retinoic Acid Induces Depression-Like Behavior by Altering the Activity of Dentate Granule Cells.
Su XH; Li WP; Wang YJ; Liu J; Liu JY; Jiang Y; Peng FH
Neurotherapeutics; 2022 Jan; 19(1):421-433. PubMed ID: 34893965
[TBL] [Abstract][Full Text] [Related]
5. A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.
Wróbel A; Szopa A; Serefko A; Poleszak E
Molecules; 2020 Mar; 25(6):. PubMed ID: 32197469
[TBL] [Abstract][Full Text] [Related]
6. Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders.
Liu HT; Chen CY; Kuo HC
J Formos Med Assoc; 2010 Dec; 109(12):862-78. PubMed ID: 21195884
[TBL] [Abstract][Full Text] [Related]
7. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.
Cerruto MA; Asimakopoulos AD; Artibani W; Del Popolo G; La Martina M; Carone R; Finazzi-Agrò E
Urol Int; 2012; 89(1):1-8. PubMed ID: 22738896
[TBL] [Abstract][Full Text] [Related]
8. Blebbistatin, a Myosin II Inhibitor, Exerts Antidepressant-Like Activity and Suppresses Detrusor Overactivity in an Animal Model of Depression Coexisting with Overactive Bladder.
Wróbel A; Doboszewska U; Rechberger E; Bańczerowska-Górska M; Czuczwar P; Poleszak E; Dudka J; Wlaź P; Miotła P; Wlaźlak E; Rechberger T
Neurotox Res; 2019 Jan; 35(1):196-207. PubMed ID: 30155683
[TBL] [Abstract][Full Text] [Related]
9. SN003, a CRF
Wróbel A; Doboszewska U; Rechberger E; Wlaź P; Rechberger T
Eur J Pharmacol; 2017 Oct; 812():216-224. PubMed ID: 28705713
[TBL] [Abstract][Full Text] [Related]
10. The influence of duloxetine on detrusor overactivity in rats with depression induced by 13-cis-retinoic acid.
Wróbel A; Rechberger E; Rechberger T
Int Urogynecol J; 2018 Jul; 29(7):987-995. PubMed ID: 28762178
[TBL] [Abstract][Full Text] [Related]
11. Intravesical administration of blebbistatin prevents cyclophosphamide-induced toxicity of the urinary bladder in female Wistar rats.
Wróbel A; Serefko A; Bańczerowska-Górska M; Szopa A; Dudka J; Poleszak E
Neurourol Urodyn; 2019 Apr; 38(4):1044-1052. PubMed ID: 30869827
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo relaxation of urinary bladder smooth muscle by the selective myosin II inhibitor, blebbistatin.
Zhang X; Kuppam DS; Melman A; DiSanto ME
BJU Int; 2011 Jan; 107(2):310-7. PubMed ID: 20482706
[TBL] [Abstract][Full Text] [Related]
13. An animal model of detrusor overactivity induced by depression.
Wróbel A; Rechberger T
J Pharmacol Toxicol Methods; 2016; 80():19-25. PubMed ID: 27050558
[TBL] [Abstract][Full Text] [Related]
14. Novel biomarkers of overactive bladder syndrome.
Wróbel AF; Kluz T; Surkont G; Wlaźlak E; Skorupski P; Filipczak A; Rechberger T
Ginekol Pol; 2017; 88(10):568-573. PubMed ID: 29192418
[TBL] [Abstract][Full Text] [Related]
15. BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity.
Kashyap MP; Pore SK; de Groat WC; Chermansky CJ; Yoshimura N; Tyagi P
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F45-F56. PubMed ID: 29092846
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
